Relmada Therapeutics (RLMD) Non Operating Income (2014 - 2026)
Relmada Therapeutics (RLMD) reported Non Operating Income of $409798.0 for Q1 2026, down 37.81% year-over-year from $658970.0 in Q1 2025, and down 11.94% on a QoQ basis from $465352.0 in Q4 2025.
Relmada Therapeutics (RLMD) has 13 years of Non Operating Income data on file, last reported at $409798.0 in Q1 2026.
- Quarterly Non Operating Income fell 37.81% year-over-year to $409798.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 57.02% YoY) and the FY2025 annual result came in at $1.7 million, down 56.16% from the prior year.
- Non Operating Income eased to $409798.0 in Q1 2026 per RLMD's latest filing, from $465352.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $5.6 million in Q2 2022 and bottomed at -$1.4 million in Q1 2022.
- The 5-year median for Non Operating Income is $690580.0 (2023), against an average of $891312.7.
- Peak annual rise in Non Operating Income reached 6292.38% in 2022, while the deepest fall reached 1536.53% in 2022.
- Tracing RLMD's Non Operating Income over 5 years: stood at $758055.0 in 2022, then jumped by 119.53% to $1.7 million in 2023, then tumbled by 74.86% to $418418.0 in 2024, then gained by 11.22% to $465352.0 in 2025, then declined by 11.94% to $409798.0 in 2026.
- Per Business Quant, the three latest RLMD Non Operating Income figures stand at $409798.0 (Q1 2026), $465352.0 (Q4 2025), and $235850.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | 409,798.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 409,798.00 |
| Dec 31, 2025 | 465,352.00 |
| Sep 30, 2025 | 235,850.00 |
| Jun 30, 2025 | 354,864.00 |
| Mar 31, 2025 | 658,970.00 |
| Dec 31, 2024 | 418,418.00 |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 1.05 Mn |
| Mar 31, 2024 | 1.16 Mn |
| Dec 31, 2023 | 1.66 Mn |
| Sep 30, 2023 | 690,580.00 |
| Jun 30, 2023 | 723,772.00 |
| Mar 31, 2023 | 1.83 Mn |
| Dec 31, 2022 | 758,055.00 |
| Sep 30, 2022 | -681,546.00 |
| Jun 30, 2022 | 5.58 Mn |
| Mar 31, 2022 | -1.45 Mn |
| Dec 31, 2021 | -195,719.00 |
| Sep 30, 2021 | 47,444.00 |
| Jun 30, 2021 | -90,064.00 |
| Mar 31, 2021 | 190,022.00 |
| Dec 31, 2020 | 161,321.00 |
| Sep 30, 2020 | 281,075.00 |
| Jun 30, 2020 | 1.64 Mn |
| Mar 31, 2020 | -698,878.00 |
| Dec 31, 2019 | 75,063.00 |
| Sep 30, 2019 | 37,916.00 |
| Jun 30, 2019 | 13,110.00 |
| Mar 31, 2019 | 15,939.00 |
| Dec 31, 2018 | -3.65 Mn |
| Sep 30, 2018 | -968,863.00 |
| Mar 31, 2018 | -651,973.00 |
| Dec 31, 2017 | 29,235.00 |
| Sep 30, 2017 | -830.00 |
| Jun 30, 2017 | 149,267.00 |
| Mar 31, 2017 | 301,458.00 |
| Dec 31, 2016 | 505,572.00 |
| Sep 30, 2016 | -23,985.00 |
| Jun 30, 2016 | -214,918.00 |
| Mar 31, 2016 | 887,308.00 |
| Dec 31, 2015 | 3.26 Mn |
| Sep 30, 2015 | 9.29 Mn |
| Jun 30, 2015 | 10.45 Mn |
| Mar 31, 2015 | 2.12 Mn |
| Dec 31, 2014 | 9.84 Mn |
| Sep 30, 2014 | -26.12 Mn |
| Jun 30, 2014 | -8.39 Mn |
| Mar 31, 2014 | 7.21 Mn |